MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-05-2023
Heska Corporation Net Income 2011-2026 | HSKA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.9 M | -1.15 M | -14.4 M | -1.46 M | 5.85 M | 9.95 M | 10.5 M | 5.24 M | 2.6 M | -1.2 M | 1.2 M | 2.14 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.5 M | -19.9 M | -49.7 K |
Quarterly Net Income Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.1 M | - | -436 K | -5.25 M | -9.99 M | -9.99 M | -1.9 M | -1.9 M | 1.87 M | - | -5.22 M | -6.36 M | -5.29 M | -1.73 M | -310 K | -241 K | 814 K | 3.47 M | -1.67 M | 1.9 M | 2.16 M | -1.07 M | 3.08 M | 3.33 M | 4.61 M | 3.45 M | 3.35 M | 2.52 M | 1.19 M | 2.03 M | 1.42 M | 1.2 M | 598 K | 829 K | 513 K | 1.07 M | 192 K | 1.18 M | 241 K | -2.23 M | -386 K | 389 K | -32 K | 262 K | 584 K | 484 K | 288 K | 457 K | 916 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.61 M | -10.1 M | -420 K |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-6.46 M | $ 19.11 | 0.47 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 5.31 | 4.89 % | $ 156 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.49 | -2.36 % | $ 215 M |  China |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 38.74 | -0.41 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
3.9 B | $ 228.43 | -0.21 % | $ 167 B | USA |
 |
DexCom
DXCM
|
542 M | $ 66.86 | 0.74 % | $ 25.8 B | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.56 | 1.96 % | $ 1.98 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-59.4 M | $ 11.42 | 0.35 % | $ 324 M | Israel |
 |
IQVIA Holdings
IQV
|
1.37 B | $ 225.43 | 0.01 % | $ 40.9 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-865 M | $ 101.79 | 0.23 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 25.95 | -1.24 % | $ 785 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
-190 M | $ 19.2 | 1.91 % | $ 1.03 B | USA |
 |
Celcuity
CELC
|
-112 M | $ 100.08 | 0.34 % | $ 3.95 B | USA |
 |
Anixa Biosciences
ANIX
|
-12.6 M | $ 3.09 | -0.96 % | $ 98.6 K | USA |
 |
Myriad Genetics
MYGN
|
-127 M | $ 6.22 | 1.14 % | $ 564 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-11.5 M | $ 4.26 | -5.96 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
-78.7 M | $ 11.76 | - | $ 1.49 B | USA |
 |
Guardant Health
GH
|
-436 M | $ 101.08 | -1.04 % | $ 12.4 B | USA |
 |
National Research Corporation
NRC
|
31 M | $ 18.42 | -1.89 % | $ 452 M | USA |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
OPKO Health
OPK
|
14 M | $ 1.26 | 0.4 % | $ 874 M | USA |
 |
Precipio
PRPO
|
-5.85 M | $ 24.92 | 8.46 % | $ 32.3 M | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 7.76 | -2.52 % | $ 460 M | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Illumina
ILMN
|
-1.22 B | $ 132.27 | 0.85 % | $ 21 B | USA |
 |
Charles River Laboratories International
CRL
|
22.2 M | $ 200.24 | 0.38 % | $ 10.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
871 M | $ 172.79 | -0.43 % | $ 19.2 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 6.84 | 0.51 % | $ 887 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 27.14 | 0.22 % | $ 20 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
746 M | $ 250.12 | -0.3 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 186.86 | 2.55 % | $ 15.4 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
888 M | $ 666.09 | -1.54 % | $ 54.9 B | USA |
 |
Lantheus Holdings
LNTH
|
312 M | $ 66.89 | 0.51 % | $ 4.63 B | USA |
 |
Mettler-Toledo International
MTD
|
863 M | $ 1 395.51 | 0.09 % | $ 29.6 B |  Schweiz |
 |
Agilent Technologies
A
|
1.21 B | $ 136.02 | -0.04 % | $ 41.4 B | USA |